Context: Mutations in the gene encoding Mediator complex subunit MED12 are dominant drivers of uterine fibroids (UFs) in women of diverse racial and ethnic origins. Previously, we showed that UF-linked mutations in MED12 disrupt its ability to activate cyclin C-CDK8/19 in Mediator. However, validation of Mediator kinase disruption in the clinically relevant setting of MED12-mutant UFs is currently lacking. Objective: The objective of this study was twofold. First, to extend the ethnic distribution profile of MED12 mutations by establishing their frequency in UFs from Hispanic women of South Texas. Second, to examine the impact of MED12 mutations on Mediator kinase activity in patient-derived UFs. Methods: We screened 219 UFs from 76 women, including 170 tumors from 57 Hispanic patients, for MED12 exon 2 mutations, and further examined CDK8/19 activity in Mediator complexes immunoprecipitated from MED12 mutation-negative and MED12 mutation-positive UFs. Results: MED12 exon 2 mutations in UFs from Hispanic women are somatic in nature, predominantly monoallelic, and occur at high frequency (54.1%). We identified a minimal cyclin C-CDK8 activation domain on MED12 spanning amino acids 15 through 80 that includes all recorded UF-linked mutations in MED12, suggesting that disruption of Mediator kinase activity is a principal biochemical defect arising from these pathogenic alterations. Analysis of Mediator complexes recovered from patient UFs confirmed this, revealing that Mediator kinase activity is selectively impaired in MED12-mutant UFs. Conclusions: MED12 mutations are important drivers of UF formation in Hispanic women of South Texas. MED12 mutations disrupt Mediator kinase activity, implicating altered CDK8/19 function in UF pathogenesis.
Context: Mutations in the gene encoding Mediator complex subunit MED12 are dominant drivers of uterine fibroids (UFs) in women of diverse racial and ethnic origins. Previously, we showed that UF-linked mutations in MED12 disrupt its ability to activate cyclin C-CDK8/19 in Mediator. However, validation of Mediator kinase disruption in the clinically relevant setting of MED12-mutant UFs is currently lacking. Objective: The objective of this study was twofold. First, to extend the ethnic distribution profile of MED12 mutations by establishing their frequency in UFs from Hispanic women of South Texas. Second, to examine the impact of MED12 mutations on Mediator kinase activity in patient-derived UFs. Methods: We screened 219 UFs from 76 women, including 170 tumors from 57 Hispanic patients, for MED12 exon 2 mutations, and further examined CDK8/19 activity in Mediator complexes immunoprecipitated from MED12 mutation-negative and MED12 mutation-positive UFs. Results: MED12 exon 2 mutations in UFs from Hispanic women are somatic in nature, predominantly monoallelic, and occur at high frequency (54.1%). We identified a minimal cyclin C-CDK8 activation domain on MED12 spanning amino acids 15 through 80 that includes all recorded UF-linked mutations in MED12, suggesting that disruption of Mediator kinase activity is a principal biochemical defect arising from these pathogenic alterations. Analysis of Mediator complexes recovered from patient UFs confirmed this, revealing that Mediator kinase activity is selectively impaired in MED12-mutant UFs. Conclusions: MED12 mutations are important drivers of UF formation in Hispanic women of South Texas. MED12 mutations disrupt Mediator kinase activity, implicating altered CDK8/19 function in UF pathogenesis.
Authors: Kati Kämpjärvi; Min Ju Park; Miika Mehine; Nam Hee Kim; Alison D Clark; Ralf Bützow; Tom Böhling; Jan Böhm; Jukka-Pekka Mecklin; Heikki Järvinen; Ian P M Tomlinson; Zephne M van der Spuy; Jari Sjöberg; Thomas G Boyer; Pia Vahteristo Journal: Hum Mutat Date: 2014-07-21 Impact factor: 4.878
Authors: Mikko Turunen; Jason M Spaeth; Salla Keskitalo; Min Ju Park; Teemu Kivioja; Alison D Clark; Netta Mäkinen; Fangjian Gao; Kimmo Palin; Helka Nurkkala; Anna Vähärautio; Mervi Aavikko; Kati Kämpjärvi; Pia Vahteristo; Chongwoo A Kim; Lauri A Aaltonen; Markku Varjosalo; Jussi Taipale; Thomas G Boyer Journal: Cell Rep Date: 2014-04-18 Impact factor: 9.423
Authors: Masanori Ono; Ping Yin; Antonia Navarro; Molly B Moravek; John S Coon; Stacy A Druschitz; Vanida Ann Serna; Wenan Qiang; David C Brooks; Saurabh S Malpani; Jiajia Ma; Cihangir Mutlu Ercan; Navdha Mittal; Diana Monsivais; Matthew T Dyson; Alex Yemelyanov; Tetsuo Maruyama; Debabrata Chakravarti; J Julie Kim; Takeshi Kurita; Cara J Gottardi; Serdar E Bulun Journal: Proc Natl Acad Sci U S A Date: 2013-09-30 Impact factor: 11.205
Authors: Zachary C Poss; Christopher C Ebmeier; Aaron T Odell; Anupong Tangpeerachaikul; Thomas Lee; Henry E Pelish; Matthew D Shair; Robin D Dowell; William M Old; Dylan J Taatjes Journal: Cell Rep Date: 2016-03-31 Impact factor: 9.423
Authors: Netta Mäkinen; Hanna-Riikka Heinonen; Shane Moore; Ian P M Tomlinson; Zephne M van der Spuy; Lauri A Aaltonen Journal: Oncotarget Date: 2011-12
Authors: Martina S J McDermott; Alexander A Chumanevich; Chang-Uk Lim; Jiaxin Liang; Mengqian Chen; Serena Altilia; David Oliver; James M Rae; Michael Shtutman; Hippokratis Kiaris; Balázs Győrffy; Igor B Roninson; Eugenia V Broude Journal: Oncotarget Date: 2017-02-21
Authors: Michał Ciebiera; Marta Włodarczyk; Stanisław Zgliczyński; Tomasz Łoziński; Klaudia Walczak; Artur Czekierdowski Journal: Int J Mol Sci Date: 2020-04-24 Impact factor: 5.923
Authors: Sribalasubashini Muralimanoharan; Ross Shamby; Nicholas Stansbury; Robert Schenken; Barbara de la Pena Avalos; Samin Javanmardi; Eloise Dray; Patrick Sung; Thomas G Boyer Journal: Sci Rep Date: 2022-04-13 Impact factor: 4.379
Authors: Qiwei Yang; Michal Ciebiera; Maria Victoria Bariani; Mohamed Ali; Hoda Elkafas; Thomas G Boyer; Ayman Al-Hendy Journal: Endocr Rev Date: 2022-07-13 Impact factor: 25.261